20 studies found for:    "Plasma cell leukemia"
Show Display Options
RSS Create an RSS feed from your search for:
"Plasma cell leukemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
Condition: Primary Plasma Cell Leukemia
Intervention: Drug: Lenalidomide, dexamethasone
2 Unknown  Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Liposome doxorubicin;   Drug: Dexamethasone
3 Recruiting Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia
Conditions: Plasma Cell Leukemia;   Plasma Cell Myeloma;   Plasmacytoma
Interventions: Drug: Dexamethasone;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Pomalidomide
4 Active, not recruiting Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Mantle Cell Lymphoma in Relapse;   Diffuse Large B Cell Lymphoma in Relapse;   Other B Cell Lymphoma in Relapse;   Plasma Cell Leukemia
Intervention: Biological: SNS01-T
5 Completed
Has Results
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Bortezomib;   Drug: Melphalan;   Procedure: PBSCT
6 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
7 Not yet recruiting Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
8 Active, not recruiting Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70
Condition: Multiple Myeloma
Intervention: Drug: PAD-VCD
9 Not yet recruiting Allo HSCT Using RIC for Hematological Diseases
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
Interventions: Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
10 Recruiting Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Conditions: Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Myeloproliferative Disorders;   Multiple Myeloma;   Plasma Cell Neoplasm;   Plasma Cell Dyscrasia;   Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
11 Recruiting Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Conditions: Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
Interventions: Biological: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Biological: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
12 Not yet recruiting Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Intervention: Drug: Bendamustine
13 Completed A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;   Drug: Dexamethasone, steroid; oral
14 Terminated
Has Results
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Conditions: Multiple Myeloma;   Plasma Cell Leukemia
Interventions: Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
15 Completed A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous;   Drug: Dexamethasone, steroid; oral;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
16 Active, not recruiting Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Conditions: Adult Acute Myeloid Leukemia in Remission;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndrome;   Childhood Renal Cell Carcinoma;   Chronic Myelomonocytic Leukemia;   Clear Cell Renal Cell Carcinoma;   de Novo Myelodysplastic Syndrome;   Metastatic Renal Cell Cancer;   Previously Treated Myelodysplastic Syndrome;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Renal Medullary Carcinoma;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Fludarabine Phosphate;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
17 Recruiting SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Conditions: Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
Interventions: Biological: Incomplete Freund's Adjuvant;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Sargramostim;   Biological: SVN53-67/M57-KLH Peptide Vaccine
18 Terminated
Has Results
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Conditions: Multiple Myeloma;   Leukemia, Plasma Cell
Interventions: Drug: Carfilzomib;   Drug: Melphalan;   Drug: Filgrastim
19 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
20 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim

Indicates status has not been verified in more than two years